Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy

Lung Cancer

Volumn 55, Issue 3, 2007, Pages 343-348

  Fujiwara, Yoshiro ^a   Kiura, Katsuyuki ^a   Hotta, Katsuyuki ^a   Tabata, Masahiro ^a   Takigawa, Nagio ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Hepatic dysfunction; Lung cancer; Overweight; Risk factor

Indexed keywords

AMRUBICIN; IRINOTECAN; PLATINUM;

ADULT; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CONFIDENCE INTERVAL; CYTOTOXICITY; FEMALE; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME SERIES ANALYSIS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BODY MASS INDEX; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; OVERWEIGHT; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33847332205     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.10.014     Document Type: Article

References (26)

1. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
2. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
3. Perry M.C. The chemotherapy source book. 2nd ed. (1996), Williams & Wilkins
4. Yamamoto N., Tamura T., Murakami H., Shimoyama T., Nokihara H., Ueda Y., et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 23 (2005) 1061-1069
5. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39 (2000) 215-231
6. Rodvold K.A., Rushing D.A., and Tewksbury D.A. Doxorubicin clearance in the obese. J Clin Oncol 6 (1988) 1321-1327
7. Lind M.J., Margison J.M., Cerny T., Thatcher N., and Wilkinson P.M. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25 (1989) 139-142
8. Miya T., Goya T., Fujii H., Ohtsu T., Itoh K., Igarashi T., et al. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 19 (2001) 61-67
9. Hruban R.H., Sternberg S.S., Meyers P., Fleisher M., Menendez-Botet C., and Boitnott J.K. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest 9 (1991) 263-268
10. Feenstra J., Vermeer R.J., and Stricker B.H. Fatal hepatic coma attributed to paclitaxel. J Natl Cancer Inst 89 (1997) 582-584
11. Robinson K., Lambiase L., Li J., Monteiro C., and Schiff M. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 48 (2003) 1804-1808
12. WHO. Obesity: preventing and managing the global epidemic. Report on a WHO Consultation on Obesity, Geneva, 3-5 June, 1997. WHO/NUT/NCD/98.1. Technical Report Series Number 894. World Health Organization, Geneva, 2000.
13. Hotta K., Takigawa N., Kiura K., Tabata M., Umemura S., Ogino A., et al. Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res 25 (2005) 2429-2434
14. Yamamoto N., Fukuoka M., Negoro S.I., Nakagawa K., Saito H., Matsui K., et al. Randomised phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br J Cancer 90 (2004) 87-92
15. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
16. Kubota K., Nishiwaki Y., Ohashi Y., Saijo N., Ohe Y., Tamura T., et al. The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22 (2004) 616 (Abstr 7006)
17. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21 (2003) 3016-3024
18. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 (2001) 3210-3218
19. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
20. King P.D., and Perry M.C. Hepatotoxicity of chemotherapy. Oncologist 6 (2001) 162-176
21. Georgiadis M.S., Steinberg S.M., Hankins L.A., Ihde D.C., and Johnson B.E. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst 87 (1995) 361-366
22. Rosner G.L., Hargis J.B., Hollis D.R., Budman D.R., Weiss R.B., Henderson I.C., et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 14 (1996) 3000-3008
23. Meyerhardt J.A., Tepper J.E., Niedzwiecki D., Hollis D.R., McCollum A.D., Brady D., et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 22 (2004) 648-657
24. Shiwaku K., Anuurad E., Enkhmaa B., Nogi A., Kitajima K., Shimono K., et al. Overweight Japanese with body mass indexes of 23.0-24.9 have higher risks for obesity-associated disorders: a comparison of Japanese and Mongolians. Int J Obes Relat Metab Disord 28 (2004) 152-158
25. Shirai K. Evaluation of obesity and diagnostic criteria of obesity as a disease for Japanese. Nippon Rinsho 59 (2001) 578-585 (in Japanese)
26. Gandara D.R., Ohe Y., Kubota K., Nishiwaki Y., Ariyoshi Y., Saijo N., et al. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): a model for prospective comparison of cooperative group trials. Proc Am Soc Clin Oncol 22 (2004) 616 (Abstr 7007)